Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)

First-line triplet chemotherapy including a taxane may prolong survival in patients with metastatic esophagogastric cancer. The added toxicity of the taxane might be minimized by using nab-paclitaxel. The aim of this phase I study was to determine the feasibility of combining nab-paclitaxel with the...

Descripción completa

Detalles Bibliográficos
Autores principales: Schokker, Sandor, van der Woude, Stephanie O., van Kleef, Jessy Joy, van Zoen, Daan J., van Oijen, Martijn G. H., Mearadji, Banafsche, Beenen, Ludo F. M., Stroes, Charlotte I., Waasdorp, Cynthia, Jibodh, R. Aarti, Creemers, Aafke, Meijer, Sybren L., Hooijer, Gerrit K. J., Punt, Cornelis J. A., Bijlsma, Maarten F., van Laarhoven, Hanneke W. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627561/
https://www.ncbi.nlm.nih.gov/pubmed/31207904
http://dx.doi.org/10.3390/cancers11060827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627561/
https://www.ncbi.nlm.nih.gov/pubmed/31207904
http://dx.doi.org/10.3390/cancers11060827

Ejemplares similares